Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 703,800 shares, a growth of 22.5% from the October 31st total of 574,700 shares. Based on an average daily trading volume, of 200,500 shares, the short-interest ratio is presently 3.5 days. Approximately 3.6% of the shares of the stock are sold short.

Hedge Funds Weigh In On Talaris Therapeutics

A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Talaris Therapeutics during the 3rd quarter worth approximately $27,000. Amalgamated Bank bought a new stake in Talaris Therapeutics during the 1st quarter worth approximately $31,000. Commonwealth Equity Services LLC bought a new position in Talaris Therapeutics in the 3rd quarter valued at $34,000. Prospera Financial Services Inc bought a new position in Talaris Therapeutics in the 3rd quarter valued at $34,000. Finally, Values First Advisors Inc. bought a new position in Talaris Therapeutics in the 2nd quarter valued at $53,000. 67.99% of the stock is owned by institutional investors and hedge funds.

Talaris Therapeutics Price Performance

Shares of NASDAQ TALS traded down $0.03 during trading hours on Thursday, hitting $1.43. 1,395 shares of the company's stock were exchanged, compared to its average volume of 141,180. Talaris Therapeutics has a 1-year low of $1.16 and a 1-year high of $16.63. The company's 50-day moving average price is $1.91 and its 200-day moving average price is $4.05.

Wall Street Analysts Forecast Growth

TALS has been the topic of a number of recent analyst reports. Evercore ISI boosted their target price on Talaris Therapeutics to $20.00 in a research report on Monday, August 15th. Morgan Stanley lowered their price target on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Friday, September 9th. Finally, HC Wainwright started coverage on Talaris Therapeutics in a report on Thursday, October 20th. They set a "buy" rating and a $18.00 price target on the stock.

Talaris Therapeutics Company Profile

(Get Rating)

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.

Recommended Stories

• Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
• Are the Short Sellers Still Right About Mullen Automotive stock?
• La-Z-Boy Reclines To More Comfortable Levels
• Is The Recovery Rally Here For SoFi?
• Is Apple Going To Rally Into Year End?
• Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.